Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study

T. Torres, M. J. Paiva-Lopes, M. Gonçalo, C. Claro, M. Oliveira, J. Gomes, A. P. Vieira, P. Amoedo, M. Alpalhão, M. Nogueira, F. Santiago, M. Henrique, C. Amaro, T. Esteves, J. Alves, D. Cerejeira, P. Mendes-Bastos, M. Pestana, L. Ramos, J. RochaR. Carvalho, L. Teixeira, M. Selores, A. Mota, P. Filipe

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Introduction: Atopic dermatitis (AD) is a difficult-to-treat inflammatory skin disease with a high impact on patients’ quality of life. Dupilumab, an IL-4 and IL-13 inhibitor, was the first monoclonal antibody approved for the treatment of moderate-to-severe AD and is currently approved in patients aged 6 or older. Methods: This is a nationwide, multicenter, retrospective, 48-week study designed by the Portuguese Group of AD to assess real-world efficacy and safety of dupilumab for the treatment of AD. Results: A total of 169 patients were enrolled, with a mean disease duration of 22.75 (±11.98) years. The percentage of patients achieving an improvement of at least 75% in Eczema Area and Severity Index (EASI) compared to baseline (EASI75 response) at weeks 12 and 48 was 67.6% and 74.1%, respectively. In the same timepoints, 25.0% and 44.1% achieved an EASI90 response. Patient-reported outcome measures also improved throughout the study period. Regarding safety, 32.0% of the patients developed adverse events, with conjunctivitis (26.6%), persistent facial erythema (4.7%), and arthritis/arthralgia (3.6%) as the more frequently reported. Conclusion: Data from real-world populations are crucial to guide clinicians in their daily decisions. This study provides data demonstrating that dupilumab is an effective and safe therapeutic option for AD.

Original languageEnglish
Pages (from-to)2554 - 2559
JournalJournal of Dermatological Treatment
Issue number5
Publication statusPublished - Jan 2022


  • Atopic dermatitis
  • biologics
  • dupilumab
  • treatment


Dive into the research topics of 'Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study'. Together they form a unique fingerprint.

Cite this